RonaldF.TutroneJr.MD

Urology • Garrison, MD

RFT at CUA

Join to view full profile

Dr. Tutrone is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tutrone's full profile

Already have an account?

Office
25 Crossroads Dr
Ste 306
Garrison, MD 21117
Phone+1 410-825-5454

Fax+1 410-825-5811
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1989 - 1993
SUNY Downstate Health Sciences UniversityResidency, Surgery, 1987 - 1989
Rutgers Robert Wood Johnson Medical SchoolClass of 1987

Certifications & Licensure

MD State Medical License 1993 - 2025
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2013
Top MD Consumers Checkbook
Super Doctor SuperDoctors.com
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms Start of enrollment: 2009 Jun 01
Completed
Phase 3
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
Terminated
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Terminated
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis Start of enrollment: 2014 Mar 01
Completed
Phase 2
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis Start of enrollment: 2015 Sep 23
Completed
Phase 2
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer Start of enrollment: 2021 Jun 09
Terminated
Phase 1, Phase 2
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent Start of enrollment: 2021 Jun 24
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

BPI24-026: Utilization of ExoDx Prostate Test for Prostate Cancer Risk Stratification in the African American Population.
Jason Alter, Christian J Ray, Sonia Kumar, Yiyuan Yao, Vinita Verma, Johan Skog, Ronald Tutrone, Grannum Sant> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
BPI24-025: Prostate Biopsies Against Medical Advice: Unveiling New Biomarker Insights for Men.
Jason Alter, Sonia Kumar, Johan Skog, Vinita Verma, Kyle Schimizzi, Yiyuan Yao, Christian J Ray, Brian Haynes, Ronald Tutrone> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
Daniel E Spratt, Daniel J George, Neal D Shore, Michael S Cookson, Daniel R Saltzstein, Ronald Tutrone, Alberto Bossi, Bruce A Brown, Sophia Lu, Mark Fallick, Sarah Ha...> ;JAMA Oncology. 2024 Mar 7
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Saad, F., Tombal, B., Saltzstein, D., Hanson, S., Brown, B., Lu, S., Fallick, M., Tutrone, R., George, D., Bailen, J., Cookson, M., Shore, N.> ;European Urology Oncology. 2023 Dec 23
1 citations
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
Freedland, S., Gleave, M., De Giorgi, U., Rannikko, A., Pieczonka, C., Tutrone, R., Venugopal, B., Woo, H., Ramirez-Backhaus, M., Supiot, S., Lantz, A., Ganguli, A., I...> ;NEJM Evidence. 2023 Dec 1
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer.
Fred Saad, Daniel J George, Michael S Cookson, Daniel R Saltzstein, Ronald Tutrone, Alberto Bossi, Bruce Brown, Bryan Selby, Sophia Lu, Bertrand Tombal, Neal D Shore> ;Cancers. 2023 Oct 5
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Neal D Shore, Bryan A Mehlhaff, Michael S Cookson, Daniel R Saltzstein, Ronald Tutrone, Bruce Brown, Sophia Lu, Mark Fallick, Sarah Hanson, Fred Saad> ;Advances in Therapy. 2023 Nov 1
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.
Ronald Tutrone, Ben Lowentritt, Brian Neuman, Michael J Donovan, Elliot Hallmark, T Jeffrey Cole, Yiyuan Yao, Claire Biesecker, Sonia Kumar, Vinita Verma, Grannum R Sa...> ;Prostate Cancer and Prostatic Diseases. 2024 Mar 1
4 citations
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.
Ronald Tutrone, Ben Lowentritt, Brian Neuman, Michael J Donovan, Elliot Hallmark, T Jeffrey Cole, Yiyuan Yao, Claire Biesecker, Sonia Kumar, Vinita Verma, Grannum R Sa...> ;Prostate Cancer and Prostatic Diseases. 2023 Sep 1
1 citations
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
Jose De La Cerda, Curtis Dunshee, Lawrence Gervasi, Paul Sieber, Laurence Belkoff, Ronald Tutrone, Sophia Lu, Sergio C Gatoulis, Bruce Brown, Elizabeth Migoya, Neal Shore> ;Targeted Oncology. 2023 May 1
6 citations
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Kim N Chi, Neil Fleshner, Vincenzo Emanuele Chiuri, Siska Van Bruwaene, Jason Hafron, Douglas G McNeel, Peter De Porre, Raymond Scott Maul, Mahesh Daksh, Xiaogang Zhon...> ;The Oncologist. 2023 May 8
Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
Daniel J George, Fred Saad, Michael S Cookson, Daniel R Saltzstein, Ronald Tutrone, Alberto Bossi, Bruce Brown, Bryan Selby, Sophia Lu, David Buckley, Bertrand Tombal,...> ;Clinical Genitourinary Cancer. 2023 Jun 1
Transurethral Vapor Ablation in Patients with Intermediate-Risk Localized Prostate Cancer.
Christopher M Dixon, Richard M Levin, Christopher H Cantrill, Mikhail Regelman, Benjamin Spilseth, Ronald F Tutrone Jr, Michael A White, Aaron J Milbank, Christopher A...> ;Journal of Endourology. 2023 Feb 1
13 citations
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Re...
Mark C Markowski, Ronald Tutrone, Christopher Pieczonka, K Gary Barnette, Robert H Getzenberg, Domingo Rodriguez, Mitchell S Steiner, Daniel R Saltzstein, Mario A Eise...> ;Clinical Cancer Research. 2022 Jul 1
7 citations
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
Mark N Stein, Lawrence Fong, Ronald Tutrone, Anthony Mega, Elaine T Lam, Megan Parsi, Surya Vangala, Andres A Gutierrez, Naomi B Haas> ;The Oncologist. 2022 Jun 8
16 citations
Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
Alexander Kretschmer, Ronald Tutrone, Jason Alter, Elena Berg, Christian Fischer, Sonia Kumar, Phillipp Torkler, Vasisht Tadigotla, Michael Donovan, Grannum Sant, Joha...> ;World Journal of Urology. 2022 Apr 1
9 citations
Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy.
Alexander Kretschmer, Holger Kajau, Eric Margolis, Ronald Tutrone, Tobias Grimm, Matthias Trottmann, Christian Stief, Georg Stoll, Christian A Fischer, Claudia Flinspa...> ;Scientific Reports. 2022 Mar 21
34 citations
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies.
Erik Margolis, Gordon D. Brown, Alan W. Partin, Ballentine Carter, James M. McKiernan, Ronald F. Tutrone, Phillipp Torkler, Christian Fischer, Vasisht Tadigotla, Mikke...> ;Prostate Cancer and Prostatic Diseases. 2021 Sep 30
Reply Letter By Author.
Ronald F. Tutrone, William Schiff> ;The Canadian Journal of Urology. 2021 Feb 1
9 citations
Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection.
Ronald F. Tutrone, William Schiff> ;The Canadian Journal of Urology. 2020 Jun 1
Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data.
Celestia S. Higano, Andrew J. Armstrong, Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher Michael Pieczonka, David F. Penson, Neal...> ;Cancer. 2020 Jun 15
8 citations
Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer
Neal D. Shore, Paul F. Schellhammer, Ronald F. Tutrone, Neil Mariados, Stacey Harrelson> ;Clinical Genitourinary Cancer. 2020 Apr 18
201 citations
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore, Fred Saad, Michael S. Cookson, Daniel J. George, Daniel Saltzstein, Ronald Tutrone, Hideyuki Akaza, Alberto Bossi, David van Veenhuyzen, Bryan Selby, Xi...> ;The New England Journal of Medicine. 2020 May 29
82 citations
Clinical utility of the exosome based ExoDx Prostate( IntelliScore ) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL
Ronald F. Tutrone, Michael J. Donovan, Phillipp Torkler, Vasisht Tadigotla, Tom McLain, Mikkel Noerholm, Johan Skog, James M. McKiernan> ;Prostate Cancer and Prostatic Diseases. 2020 May 7
11 citations
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.
Neal D. Shore, Matthew P. Morrow, Trevor McMullan, Kimberly A. Kraynyak, Albert Sylvester, Khamal Bhatt, Jocelyn Cheung, Jean D. Boyer, Li Liu, Brian Sacchetta, Samant...> ;Molecular Therapy. 2020 May 6
Join now to see all

Press Mentions

Baseball Legend Cal Ripken Jr. Says His Prostate Cancer 'Could Have Been a Much Different Result' if He Hadn't Been a Sports StarSeptember 22nd, 2020
Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility StudyMay 7th, 2020
'Missing Data' on Prostate Test: Good Science or Marketing War?May 29th, 2019
Join now to see all